Ceptaris

Ceptaris Therapeutics, Inc. is a privately held, specialty pharmaceutical company that focuses on developing a proprietary gel formulation for the treatment of early-stage mycosis fungoides, a rare cancer. The company's main product is a topical mechlorethamine gel designed to treat the signs and symptoms of this condition.